Risks of Thrombocytopenia in Clozapine Users

Incidência and Magnitude of Risk

• The American Academy of Child and Adolescent Psychiatry and the American Psychiatric Association acknowledge that neutropenia/agranulocytosis is a primary hematological risk of clozapine, with a well-documented incidence, requiring mandatory monitoring 1, 2

Contexto Clínico Importante

• In pediatric studies, approximately 24% of young patients developed significant neutropenia during clozapine treatment, demonstrating an increased risk in this population, as reported by the Journal of the American Academy of Child and Adolescent Psychiatry 1
• The American Academy of Child and Adolescent Psychiatry and the American Psychiatric Association recognize that clozapine's immunomodulatory properties contribute to transient hematological changes in multiple cell lines, including neutropenia/agranulocytosis 1, 2

Considerações Práticas

• The American Academy of Child and Adolescent Psychiatry and the American Psychiatric Association note that thrombocytopenia is not listed as an absolute contraindication to clozapine use in primary guidelines, unlike agranulocytosis 1, 2